FDA staff: NPS drug effective; no significant safety imbalance

WASHINGTON (Reuters) - NPS Pharmaceuticals Inc's hormone replacement therapy Natpara reduced the need for calcium and vitamin D supplements in clinical trials, though some data was excluded due to manufacturing violations, according to a preliminary review by the U.S. Food and Drug Administration.

via Reuters: Health News Read More Here..